Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Real World Analysis of the Efficacy, Prognosis and Safety of Daratumumab, Carfilzomib, and Dexamethasone (DKD) in Relapsed or Refractory Multiple Myeloma Patients

Chengcheng Fu, Hongying You, Song Jin, Panfeng Wang, Lingzhi Yan, Liying Zhang, Tingting Lu, Xiao Gao, Lei Jiang, Hongchun Qiu, Jingjing Shang, Yingying Zhai, Weiqin Yao, Shuang Yan, Zhi Yan, Depei Wu

Blood (2024) 144 (Supplement 1): 6992.

https://doi.org/10.1182/blood-2024-210102

Published: 2024

Journal Articles

Interim Analysis of Dara VRD in the Treatment of TE-NDMM Patients with Standard Risk Who Refused to Accept ASCT As First Line in China

Chengcheng Fu, Jing Wang, Song Jin, Lingzhi Yan, Jingjing Shang, Weiqin Yao, Xiaolan Shi, Zhi Yan, Depei Wu

Blood (2024) 144 (Supplement 1): 1997.

https://doi.org/10.1182/blood-2024-209260

Published: 2024

Journal Articles

5-Year Follow-up of Combined Infusion of Anti-CD19 and Anti-BCMA CAR-T after ASCT for High-Risk Newly Diagnosed Multiple Myeloma

Xiaolan Shi, Chengcheng Fu, Lingzhi Yan, Yingying Zhai, Zhi Yan, Jingjing Shang, Song Jin, Xingyue Wu, Hongying You, Shuang Yan, Weiqin Yao, Liqing Kang, Lei Yu, Depei Wu

Blood (2024) 144 (Supplement 1): 4766.

https://doi.org/10.1182/blood-2024-207687

Published: 2024

Journal Articles

Low Intensity Daratumumab to Treat Rersistent/Recurrent Minimal Residual Disease in Multiple Myeloma

Lingzhi Yan, Xiaolan Shi, Jing Wang, Song Jin, Ying Yao, Panfeng Wang, Jingjing Shang, Yingying Zhai, Shuang Yan, Yun Xu, Jiajia Meng, Weiqin Yao, Xiao Ma, Chengcheng Fu, Depei Wu

Blood (2024) 144 (Supplement 1): 4750.

https://doi.org/10.1182/blood-2024-205595

Published: 2024

Journal Articles

A First-in-Human Study of CT0590, a Triple Knock-out, Allogeneic CAR T-Cell Therapy Targeting BCMA and NKG2A, in Subjects with Relapsed/Refractory Multiple Myeloma

Chengcheng Fu, Lingzhi Yan, Weiqin Yao, Jingjing Shang, Song Jin, Shuang Yan, Fang Tang, Ziling Zhu, Depei Wu, Ying Li, Nishanthan Rajakumaraswamy, Wei Zheng, Hua Jiang, Zhaohui Liao, Zonghai Li

Blood (2024) 144 (Supplement 1): 4843.

https://doi.org/10.1182/blood-2024-204401

Published: 2024

Journal Articles

CNVs Numbers Scoring System Was a Good Prognostic Risk Stratification for NDMM with Whole Genomic Mapping Array

Zhao Zeng, Chengcheng Fu, Jinlan Pan, Jiao Lu, Jingjing Shang, Zhiyu Zhang, Hongying You, Wanhui Yan, Chunxiao Wu, Qinrong Wang, Qian Wang, Lijun Wen, Song Jin, Lingzhi Yan, Suning Chen, De-pei Wu

Blood (2023) 142 (Supplement 1): 4725.

https://doi.org/10.1182/blood-2023-184504

Published: 2023

Journal Articles

IMWG /ECOG Frailty Score Was a Good Indicator for ASCT Candidate Selection for NDMM in China from a Hcmmd Retrospective Study

Xingyue Wu, Chengcheng Fu, Hongmiao Shen, Hongying You, Yingying Zhai, Jing Wang, Zhi Yan, Shuang Yan, Weiqin Yao, Jiao Lu, Jingjing Shang, Song Jin, Xiaolan Shi, Lingzhi Yan, De-Pei Wu

Blood (2023) 142 (Supplement 1): 7061.

https://doi.org/10.1182/blood-2023-185763

Published: 2023

Journal Articles

Selinexor, Daratumumab and Dexamethasone for Patients with Multiple Myeloma Previously Treated with Lenalidomide at First Relapse: A Real-World Study

Yingying Zhai, Lingzhi Yan, Song Jin, Jingjing Shang, Xiaolan Shi, Weiqin Yao, Zhi Yan, Shuang Yan, De-pei Wu, Chengcheng Fu

Blood (2023) 142 (Supplement 1): 6739.

https://doi.org/10.1182/blood-2023-185540

Published: 2023

Journal Articles

Initial Safety and Efficacy of Daratumumab (DARA) in Combination with Bortezomib, Lenalidomide, and Dexamethasone in the Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE-NDMM) Patients with Standard Risk Who Refused to Accept ASCT As First Line in China

Chengcheng Fu, Jing Wang, Lingzhi Yan, Song Jin, Jingjing Shang, Xiaolan Shi, Weiqin Yao, Zhi Yan, De-Pei Wu

Blood (2023) 142 (Supplement 1): 6736.

https://doi.org/10.1182/blood-2023-185263

Published: 2023

Journal Articles

Three-Year Follow-up on Efficacy and Safety Results from Phase 1 Lummicar Study 1 of Zevorcabtagene Autoleucel in Chinese Patients with Relapsed or Refractory Multiple Myeloma

Chengcheng Fu, Wenming Chen, Zhen Cai, Lingzhi Yan, Huijuan Wang, Jingjing Shang, Yin Wu, Shuang Yan, Wen Gao, Xiaolan Shi, Xiaoyan Han, Fang Tang, Gaofeng Zheng, Yanling Wen, Xingxing Meng, Wei Zheng, Huamao Wang, Zonghai Li

Blood (2023) 142 (Supplement 1): 4845.

https://doi.org/10.1182/blood-2023-184373

Published: 2023

Journal Articles

11q Gain with t(11;14) or Alone Were Associated with Poor Prognosis in Newly-Diagnosed Multiple Myeloma Patients By SNP-Array Analysis and FISH

Blood (2023) 142 (Supplement 1): 1968.

https://doi.org/10.1182/blood-2023-184870

Published: 2023

Journal Articles

Efficacy and Safety of Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma with Renal Insufficiency in Real-World: A Non-Interventional Prospective Multicenter Observational Study

Chengcheng Fu, Jing Wang, Lingzhi Yan, Song Jin, Jingjing Shang, Xiaolan Shi, Weiqin Yao, Zhi Yan, Mingqing Zhu, De-Pei Wu

Blood (2023) 142 (Supplement 1): 6691.

https://doi.org/10.1182/blood-2023-185362

Published: 2023

Journal Articles

Speckle Tracking Echocardiography for the Diagnosis and Prognosis of Light Chain Cardiac Amyloidosis

Hongmiao Shen, Chengcheng Fu, Xingyue Wu, Hongying You, Zhi Yan, Weiqin Yao, Jiao Lu, Yingying Zhai, Jing Wang, Xiaolan Shi, Shuang Yan, Jingjing Shang, Song Jin, Lingzhi Yan, De-Pei Wu

Blood (2023) 142 (Supplement 1): 6743.

https://doi.org/10.1182/blood-2023-185767

Published: 2023

Journal Articles

Comparison of Next-Generation Flow Cytometry (NGF) and Next-Generation Sequencing (NGS) in the Assessment of Minimal Residual Disease in Multiple Myeloma

Qingqing Wang, Li Yao, Mingqing Zhu, Lingzhi Yan, Song Jin, Jingjing Shang, Xiaolan Shi, Yingying Zhai, Shuang Yan, Weiqin Yao, You Hongying, Depei Wu, Chengcheng Fu

Blood (2022) 140 (Supplement 1): 7249–7250.

https://doi.org/10.1182/blood-2022-157270

Published: 2022

Journal Articles

The Independent Adverse Prognostic Significance of 1q21 Gain/Amplification in Newly Diagnosed Multiple Myeloma Patients

Hongying You, Song Jin, Chunxiao Wu, Qingqing Wang, Shuang Yan, Yingying Zhai, Weiqin Yao, Xiaolan Shi, Jingjing Shang, Lingzhi Yan, Ying Yao, Jing Wang, Panfeng Wang, Jinlan Pan, Depei Wu, Chengcheng Fu

Blood (2022) 140 (Supplement 1): 10056–10057.

https://doi.org/10.1182/blood-2022-159067

Published: 2022

Journal Articles

TP53 Gene Deletion or Mutation in Newly Diagnosed Multiple Myeloma Patients By FISH with Cytoscan Arrays and Targeted Panel Sequencing

Hongying You, Hongjie Shen, Song Jin, Qingqing Wang, Shuang Yan, Yingying Zhai, Weiqin Yao, Xiaolan Shi, Jingjing Shang, Lingzhi Yan, Ying Yao, Jing Wang, Panfeng Wang, Jinlan Pan, Depei Wu, Chengcheng Fu

Blood (2022) 140 (Supplement 1): 4325–4327.

https://doi.org/10.1182/blood-2022-159272

Published: 2022

Journal Articles

Integrative Genomic and Transcriptomic Profiling Reveals Distinct Molecular Subsets in Adult Mixed Phenotype Acute Leukemia

Qian Wang, Haiping Dai, Wenzhi CAI, Qinrong Wang, Zhu Mingqing, Lingzhi Yan, Yan Yu, Hongjie Shen, Yang Xu, Ying Wang, Miao Miao, Shengli Xue, Yue Han, Xiaowen Tang, Huiying Qiu, Aining Sun, Jinyan Huang, Depei Wu, Suning Chen

Blood (2022) 140 (Supplement 1): 9198–9200.

https://doi.org/10.1182/blood-2022-156862

Published: 2022

Journal Articles

Sustainable Efficacy and Safety Results from Lummicar Study 1: A Phase 1/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma

Wenming Chen, Chengcheng Fu, Zhen Cai, Zonghai Li, Huijuan Wang, Lingzhi Yan, Yin Wu, Xiaolan Shi, Wen Gao, Shuang Yan, Wei Wang, Xiaoyan Han, Gaofeng Zheng, Yanling Wen, Jun Xiao, Huamao Wang, Xiaole Tang

Blood (2021) 138 (Supplement 1): 2821.

https://doi.org/10.1182/blood-2021-150124

Published: 2021

Journal Articles

Integrated Analysis of B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Relapsed and Refractory Multiple Myeloma Subjects By High-Risk Factors

Chengcheng Fu, Songfu Jiang, Jie Jin, Wenming Chen, Siguo Hao, Zhen Cai, Zonghai LI, Lingzhi Yan, Kang Yu, Min Yang, Huijuan Wang, Wenhao Zhang, Xiaoyan Han, Wei Wang, Hongxia Zhao

Blood (2021) 138 (Supplement 1): 1751.

https://doi.org/10.1182/blood-2021-151935

Published: 2021

Journal Articles

Phase 2 Suzhou MM02 Study: Chidamide with VRD Versus VRD in Newly Diagnosed High Risk Transplant Eligible Multiple Myeloma Patients

Weiqin Yao, Lingzhi Yan, Jingjing Shang, Song Jin, Xiaolan Shi, Shuang Yan, Depei Wu, Chengcheng Fu

Blood (2021) 138 (Supplement 1): 4765.

https://doi.org/10.1182/blood-2021-152390

Published: 2021

NARROW

Real World Analysis of the Efficacy, Prognosis and Safety of Daratumumab, Carfilzomib, and Dexamethasone (DKD) in Relapsed or Refractory Multiple Myeloma Patients

Interim Analysis of Dara VRD in the Treatment of TE-NDMM Patients with Standard Risk Who Refused to Accept ASCT As First Line in China

5-Year Follow-up of Combined Infusion of Anti-CD19 and Anti-BCMA CAR-T after ASCT for High-Risk Newly Diagnosed Multiple Myeloma

Low Intensity Daratumumab to Treat Rersistent/Recurrent Minimal Residual Disease in Multiple Myeloma

A First-in-Human Study of CT0590, a Triple Knock-out, Allogeneic CAR T-Cell Therapy Targeting BCMA and NKG2A, in Subjects with Relapsed/Refractory Multiple Myeloma

CNVs Numbers Scoring System Was a Good Prognostic Risk Stratification for NDMM with Whole Genomic Mapping Array

IMWG /ECOG Frailty Score Was a Good Indicator for ASCT Candidate Selection for NDMM in China from a Hcmmd Retrospective Study

Selinexor, Daratumumab and Dexamethasone for Patients with Multiple Myeloma Previously Treated with Lenalidomide at First Relapse: A Real-World Study

Initial Safety and Efficacy of Daratumumab (DARA) in Combination with Bortezomib, Lenalidomide, and Dexamethasone in the Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE-NDMM) Patients with Standard Risk Who Refused to Accept ASCT As First Line in China

Three-Year Follow-up on Efficacy and Safety Results from Phase 1 Lummicar Study 1 of Zevorcabtagene Autoleucel in Chinese Patients with Relapsed or Refractory Multiple Myeloma

11q Gain with t(11;14) or Alone Were Associated with Poor Prognosis in Newly-Diagnosed Multiple Myeloma Patients By SNP-Array Analysis and FISH

Efficacy and Safety of Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma with Renal Insufficiency in Real-World: A Non-Interventional Prospective Multicenter Observational Study

Speckle Tracking Echocardiography for the Diagnosis and Prognosis of Light Chain Cardiac Amyloidosis

Comparison of Next-Generation Flow Cytometry (NGF) and Next-Generation Sequencing (NGS) in the Assessment of Minimal Residual Disease in Multiple Myeloma

The Independent Adverse Prognostic Significance of 1q21 Gain/Amplification in Newly Diagnosed Multiple Myeloma Patients

TP53 Gene Deletion or Mutation in Newly Diagnosed Multiple Myeloma Patients By FISH with Cytoscan Arrays and Targeted Panel Sequencing

Integrative Genomic and Transcriptomic Profiling Reveals Distinct Molecular Subsets in Adult Mixed Phenotype Acute Leukemia

Sustainable Efficacy and Safety Results from Lummicar Study 1: A Phase 1/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma

Integrated Analysis of B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Relapsed and Refractory Multiple Myeloma Subjects By High-Risk Factors

Phase 2 Suzhou MM02 Study: Chidamide with VRD Versus VRD in Newly Diagnosed High Risk Transplant Eligible Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only